Literature DB >> 15559925

Are there long-term benefits of donepezil in Alzheimer's disease?

Sandra E Black1, John P Szalai.   

Abstract

Entities:  

Year:  2004        PMID： 15559925      PMCID： PMC524947          DOI： 10.1503/cmaj.1041615

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.

Authors:  R C Mohs; R S Doody; J C Morris; J R Ieni; S L Rogers; C A Perdomo; R D Pratt
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

Review 2.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Authors:  Krista L Lanctôt; Nathan Herrmann; Kenneth K Yau; Lyla R Khan; Barbara A Liu; Maysoon M LouLou; Thomas R Einarson
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

3.  The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.

Authors:  Murray A Raskind; Elaine R Peskind; Luc Truyen; Paul Kershaw; ChandrasekharRao Venkata Damaraju
Journal:  Arch Neurol       Date:  2004-02
  3 in total
  1 in total

Review 1.  Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

Authors:  Nathan Herrmann; Sarah A Chau; Ida Kircanski; Krista L Lanctôt
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.